Cytosorbents Corp. Form 8-K Summary
Business Context and Reporting Period
Cytosorbents Corporation (Nasdaq: CTSO) filed a Current Report on Form 8-K dated June 28, 2024. The filing details the entry into a Material Definitive Agreement involving a new credit facility to support working capital and general business requirements.
Key Financial Metrics and Transaction Terms
The Company, along with its wholly-owned subsidiary CytoSorbents Medical Inc., entered into a Loan and Security Agreement with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P. (collectively, the "Lenders").
- Total Commitment: Up to $20 million in aggregate.
- Tranche 1: $15 million total. $10 million available immediately on the Closing Date; $5 million restricted cash subject to release prior to March 31, 2025, upon meeting conditions.
- Tranche 2: Up to $5 million available upon request between July 1, 2025, and December 31, 2025, subject to conditions.
- Interest Rate: Variable rate equal to the greater of (A) Prime Rate + 5.00% or (B) 13.50% per annum.
- Repayment Terms: Interest-only payments for the initial 24 months (extendable to 30 months). Principal and accrued interest due in full on July 1, 2027 (or January 1, 2028, if Tranche 2 is fully drawn).
- Fees: 1.00% non-refundable commitment fee on the principal amount. Prepayment fees range from 3.00% (within first year) to 1.00% (after second year).
- Equity Consideration: Lenders received warrants to purchase an aggregate of 1,645,569 shares of common stock. Additionally, Lenders have a Conversion Option to convert up to $2,000,000 of principal into common stock at 120% of the Closing Price.
- Collateral: Secured by a first priority security interest in the Borrower's shares and collateral, including the Company's intellectual property.
Material Changes Versus Prior Period
This filing represents a new material agreement and does not report comparative financial performance metrics (revenue, profit, cash flow) against a prior period. The primary change is the addition of a $20 million debt facility and associated equity warrants to the Company's capital structure.
Guidance, Outlook, and Risks
Use of Proceeds: Funds will be utilized for working capital and general business requirements.
Risks and Contingencies: The agreement includes standard events of default, including non-payment, failure to perform obligations, Material Adverse Effect, insolvency, and unsatisfied judgments exceeding a defined Threshold Amount. Acceleration of the debt may occur upon these events. The Company is subject to affirmative and negative covenants typical for secured transactions.
Investor Verification Checklist
- Verify the specific conditions required to release the $5 million restricted cash portion of Tranche 1.
- Review the definition of "Material Adverse Effect" and "Threshold Amount" in the full Loan and Security Agreement (Exhibit 10.1).
- Assess the dilution impact of the 1,645,569 warrants and the potential conversion of $2 million of debt into equity.
- Confirm the current Prime Rate to calculate the effective interest cost, noting the 13.50% floor.
- Examine the Intellectual Property Security Agreement to understand the scope of assets pledged as collateral.